| AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance T O'Hare, WC Shakespeare, X Zhu, CA Eide, VM Rivera, F Wang, ... Cancer cell 16 (5), 401-412, 2009 | 1437 | 2009 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1257 | 2013 |
| Ponatinib in refractory Philadelphia chromosome–positive leukemias JE Cortes, H Kantarjian, NP Shah, D Bixby, MJ Mauro, I Flinn, T O'Hare, ... New England Journal of Medicine 367 (22), 2075-2088, 2012 | 907 | 2012 |
| A humanized system for pharmacologic control of gene expression VM Rivera, T Clackson, S Natesan, R Pollock, JF Amara, T Keenan, ... Nature medicine 2 (9), 1028-1032, 1996 | 693 | 1996 |
| Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK R Katayama, TM Khan, C Benes, E Lifshits, H Ebi, VM Rivera, ... Proceedings of the National Academy of Sciences 108 (18), 7535-7540, 2011 | 690 | 2011 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 536 | 2018 |
| Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent … WS Huang, CA Metcalf, R Sundaramoorthi, Y Wang, D Zou, RM Thomas, ... Journal of medicinal chemistry 53 (12), 4701-4719, 2010 | 405 | 2010 |
| Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum VM Rivera, X Wang, S Wardwell, NL Courage, A Volchuk, T Keenan, ... Science 287 (5454), 826-830, 2000 | 402 | 2000 |
| Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer X Ye, VM Rivera, P Zoltick, F Cerasoli Jr, MA Schnell, G Gao, JV Hughes, ... Science 283 (5398), 88-91, 1999 | 395 | 1999 |
| Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial SN Gettinger, LA Bazhenova, CJ Langer, R Salgia, KA Gold, R Rosell, ... The Lancet Oncology 17 (12), 1683-1696, 2016 | 363 | 2016 |
| Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer VM Rivera, G Gao, RL Grant, MA Schnell, PW Zoltick, LW Rozamus, ... Blood 105 (4), 1424-1430, 2005 | 362 | 2005 |
| Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models JM Gozgit, MJ Wong, L Moran, S Wardwell, QK Mohemmad, ... Molecular cancer therapeutics 11 (3), 690-699, 2012 | 357 | 2012 |
| A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity VM Rivera, CK Miranti, RP Misra, DD Ginty, RH Chen, J Blenis, ... Molecular and cellular biology, 1993 | 345 | 1993 |
| Structural mechanism of the pan‐BCR‐ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance T Zhou, L Commodore, WS Huang, Y Wang, M Thomas, J Keats, Q Xu, ... Chemical biology & drug design 77 (1), 1-11, 2011 | 342 | 2011 |
| Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase WS Huang, S Liu, D Zou, M Thomas, Y Wang, T Zhou, J Romero, ... Journal of medicinal chemistry 59 (10), 4948-4964, 2016 | 337 | 2016 |
| The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models S Zhang, R Anjum, R Squillace, S Nadworny, T Zhou, J Keats, Y Ning, ... Clinical Cancer Research 22 (22), 5527-5538, 2016 | 317 | 2016 |
| Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with … MM Mita, AC Mita, QS Chu, EK Rowinsky, GJ Fetterly, M Goldston, ... Journal of Clinical Oncology 26 (3), 361-367, 2008 | 315 | 2008 |
| Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas SP Chawla, AP Staddon, LH Baker, SM Schuetze, AW Tolcher, ... Journal of Clinical Oncology 30 (1), 78-84, 2012 | 292 | 2012 |
| A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies DA Rizzieri, E Feldman, JF Dipersio, N Gabrail, W Stock, R Strair, ... Clinical Cancer Research 14 (9), 2756-2762, 2008 | 281 | 2008 |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ... The Lancet Oncology 17 (5), 612-621, 2016 | 271 | 2016 |
